Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Consolidated Net Income (2016 - 2026)

Akebia Therapeutics has reported Consolidated Net Income over the past 10 years, most recently at -$12.2 million for Q4 2025.

  • Quarterly Consolidated Net Income rose 46.31% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 92.3% year-over-year, with the annual reading at -$5.3 million for FY2025, 92.3% up from the prior year.
  • Consolidated Net Income was -$12.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $29.0 million in Q2 2022 and troughed at -$84.3 million in Q2 2021.
  • The 5-year median for Consolidated Net Income is -$16.2 million (2023), against an average of -$25.4 million.
  • Year-over-year, Consolidated Net Income surged 134.44% in 2022 and then tumbled 3814.01% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$70.4 million in 2021, then soared by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 46.31% to -$12.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Consolidated Net Income are -$12.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).